Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents
- 26 October 2011
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 30 (3), 156-162
- https://doi.org/10.1002/hon.1019
Abstract
The ascertainment of serum free light chain (sFLC) levels has been shown to be valuable in screening for the presence of plasma cell dyscrasia as well as for baseline prognosis in newly diagnosed patients. For patients with amyloidosis and those with oligo‐secretory or non‐secretory multiple myeloma (MM), serial measurement of sFLC has also been shown to be valuable in monitoring disease status. However, in patients with a measureable, intact monoclonal protein by immunofixation (M protein), the serial measurement of sFLC remains undefined and is currently not recommended in professional guidelines. Herein, we provide data comparing sFLC with M protein as biomarkers of response in newly diagnosed patients with MM undergoing induction therapy with the novel agents thalidomide, lenalidomide and/or bortezomib. We show that although M protein appears to outperform sFLC comparatively over the course of induction therapy, the addition of FLC to M protein further informs the characterization of residual disease status post‐induction. Moreover, sFLC at the time of stem cell mobilization appears to hold prognostic power for survival endpoints following high‐dose chemotherapy/autologous stem cell transplant (HDC/SCT). These findings suggest potentially novel roles for sFLC in patients with MM with an intact M protein receiving novel agent‐based induction strategies followed by HDC/SCT. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 23 references indexed in Scilit:
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III TrialJournal of Clinical Oncology, 2010
- Multiple myeloma: chemotherapy or transplantation in the era of new drugsEuropean Journal of Haematology, 2010
- Effects of induction with novel agentsversusconventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myelomaLeukemia & Lymphoma, 2009
- Serum Free Light Chain Ratio, Total κ/λ Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple MyelomaClinical Chemistry, 2009
- Inaccuracies in 24-Hour Urine Testing for Monoclonal GammopathiesLaboratory Medicine, 2009
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersLeukemia, 2008
- Appraisal of immunoglobulin free light chain as a marker of responseBlood, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- THE FORMATION OF MYELOMA PROTEIN BY A MOUSE PLASMA CELL TUMORThe Journal of Experimental Medicine, 1958